Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (84) 84
humans (82) 82
hematology (67) 67
male (51) 51
article (49) 49
middle aged (49) 49
aged (47) 47
female (44) 44
adult (43) 43
oncology (42) 42
aged, 80 and over (29) 29
treatment outcome (23) 23
leukemia (22) 22
chronic lymphocytic leukemia (21) 21
hematology, oncology and palliative medicine (20) 20
patients (18) 18
survival (18) 18
young adult (18) 18
follow-up studies (17) 17
therapy (17) 17
abridged index medicus (15) 15
adolescent (15) 15
antineoplastic combined chemotherapy protocols - therapeutic use (15) 15
dasatinib (15) 15
leukemia, lymphocytic, chronic, b-cell - drug therapy (15) 15
mutation (15) 15
cancer (14) 14
care and treatment (14) 14
disease-free survival (14) 14
prognosis (14) 14
retrospective studies (14) 14
rituximab (14) 14
antineoplastic agents - therapeutic use (13) 13
bone marrow - pathology (13) 13
hemic and lymphatic diseases (13) 13
leukemia, lymphocytic, chronic, b-cell - pathology (13) 13
lymphomas (13) 13
cll (12) 12
ibrutinib (12) 12
lymphoma (11) 11
protein kinase inhibitors - therapeutic use (11) 11
survival rate (11) 11
chronic myeloid leukemia (10) 10
diagnosis (10) 10
imatinib (10) 10
leukemia, myelogenous, chronic, bcr-abl positive - drug therapy (10) 10
nilotinib (10) 10
recurrence (10) 10
survival analysis (10) 10
tyrosine (10) 10
chronic lymphatic leukemia (9) 9
disease progression (9) 9
minimal residual disease (9) 9
patient outcomes (9) 9
pyrimidines - therapeutic use (9) 9
transformation (9) 9
tyrosine kinase inhibitors (9) 9
chronic lymphocytic-leukemia (8) 8
health aspects (8) 8
leukemia, lymphocytic, chronic, b-cell - diagnosis (8) 8
leukemia, lymphocytic, chronic, b-cell - genetics (8) 8
leukemia, myeloid, chronic-phase - drug therapy (8) 8
chemotherapy (7) 7
chronic myelogenous leukemia (7) 7
clinical trials (7) 7
cml (7) 7
expression (7) 7
leukemia, lymphocytic, chronic, b-cell - mortality (7) 7
lymphatic leukemia (7) 7
mutations (7) 7
protein-tyrosine kinase (7) 7
pyrazoles - therapeutic use (7) 7
pyrimidines - administration & dosage (7) 7
remission induction (7) 7
risk factors (7) 7
transplantation (7) 7
trial (7) 7
antineoplastic combined chemotherapy protocols - administration & dosage (6) 6
cyclophosphamide - administration & dosage (6) 6
immunotherapy (6) 6
leukemia, myelogenous, chronic, bcr-abl positive - mortality (6) 6
lymphoma, large b-cell, diffuse - pathology (6) 6
medicine & public health (6) 6
protein kinase inhibitors - administration & dosage (6) 6
risk (6) 6
stem cell transplantation (6) 6
stem cells (6) 6
analysis (5) 5
antineoplastic combined chemotherapy protocols - adverse effects (5) 5
bcr-abl (5) 5
btk (5) 5
clinical trials as topic (5) 5
combined modality therapy (5) 5
genetic aspects (5) 5
leukemia, lymphocytic, chronic, b-cell - metabolism (5) 5
leukemia, myeloid, chronic-phase - mortality (5) 5
lymphoma, large b-cell, diffuse - drug therapy (5) 5
mantle cell lymphoma (5) 5
microenvironment (5) 5
multivariate analysis (5) 5
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Chronic lymphocytic leukemia (CLL)—Then and now
by Rai, Kanti R and Jain, Preetesh
American Journal of Hematology, ISSN 0361-8609, 03/2016, Volume 91, Issue 3, pp. 330 - 340
The field of chronic lymphocytic leukemia (CLL) has witnessed considerable change since the time clinical staging was introduced in clinical practice in 1975.... 
BRUTONS TYROSINE KINASE | INDEPENDENT PREDICTOR | FLUDARABINE PLUS CYCLOPHOSPHAMIDE | B-CELL-RECEPTOR | INITIAL THERAPY | PHASE-III | RECURRENT MUTATIONS | OPEN-LABEL | KINASE INHIBITOR IBRUTINIB | HEMATOLOGY | PREVIOUSLY UNTREATED PATIENTS | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prognosis | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Humans | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Leukemia, Lymphocytic, Chronic, B-Cell - mortality | Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy | Leukemia, Lymphocytic, Chronic, B-Cell - genetics | Leukemia, Lymphocytic, Chronic, B-Cell - pathology | Molecular Targeted Therapy - methods | Chronic lymphocytic leukemia | Chemotherapy | Analysis | Immunotherapy | Monoclonal antibodies | Cytogenetics | Tumor proteins | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Mantle cell lymphoma: 2019 update on the diagnosis, pathogenesis, prognostication, and management
by Jain, Preetesh and Wang, Michael
American Journal of Hematology, ISSN 0361-8609, 06/2019, Volume 94, Issue 6, pp. 710 - 725
Unprecedented advances in our understanding of the pathobiology, prognostication, and therapeutic options in mantle cell lymphoma (MCL) have taken place in the... 
INTRINSIC IBRUTINIB RESISTANCE | NERVOUS-SYSTEM INVOLVEMENT | 15-YEAR FOLLOW-UP | BRUTON TYROSINE KINASE | PROGRESSION-FREE SURVIVAL | PLUS RITUXIMAB | NON-HODGKIN-LYMPHOMA | PHASE-II | HIGH-DOSE CYTARABINE | HEMATOLOGY | MINIMAL RESIDUAL DISEASE
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Chronic lymphocytic leukemia (CLL)-Then and now
: Chronic lymphocytic leukemia
by Rai, Kanti R and Jain, Preetesh
American Journal of Hematology, ISSN 0361-8609, 03/2016, Volume 91, Issue 3, pp. 330 - 340
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Long‐term outcomes for patients with chronic lymphocytic leukemia who discontinue ibrutinib
by Jain, Preetesh and Thompson, Philip A and Keating, Michael and Estrov, Zeev and Ferrajoli, Alessandra and Jain, Nitin and Kantarjian, Hagop and Burger, Jan A and O'Brien, Susan and Wierda, William G
Cancer, ISSN 0008-543X, 06/2017, Volume 123, Issue 12, pp. 2268 - 2273
BACKGROUND Ibrutinib is a Bruton tyrosine kinase inhibitor and is approved for the treatment of patients with chronic lymphocytic leukemia (CLL) in frontline... 
ibrutinib | Richter transformation | Chronic lymphocytic leukemia (CLL) | venetoclax | CLL | EVOLUTION | THERAPY | ONCOLOGY | RESISTANCE | MUTATIONS | Pyrazoles - therapeutic use | Follow-Up Studies | Humans | Middle Aged | Male | Survival Rate | Disease Progression | Deprescriptions | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Drug-Related Side Effects and Adverse Reactions | Aged, 80 and over | Adult | Female | Aged | Retrospective Studies | Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy | Chronic lymphocytic leukemia | Care and treatment | Cancer patients | Health aspects | Patient outcomes | Tyrosine | Therapy | Transformation | Chronic lymphatic leukemia | Leukemia | Medical services | Agent orange | Lymphatic leukemia | Patients | Survival | Intolerance | Salvage | Mutation | Protein-tyrosine kinase | Cancer | Ibrutinib | chronic lymphocytic leukemia
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text CLL transformation after one cycle of FCR: Richter’s or EBV-associated lympho-proliferation?
by Jain, Preetesh and Burger, Jan and Khoury, Joseph D
American journal of hematology, ISSN 0361-8609, 10/2017, Volume 92, Issue 10, pp. 1113 - 1114
EBV | Richter’s transformation
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Richter's transformation in chronic lymphocytic leukemia
by Jain, Preetesh and O'Brien, Susan
Oncology (Williston Park, N.Y.), ISSN 0890-9091, 12/2012, Volume 26, Issue 12, pp. 1146 - 1152
Richter's transformation, or Richter's syndrome, is an uncommon clinicopathological condition observed in about 5% to 10% of patients with chronic lymphocytic... 
PROLYMPHOCYTIC LEUKEMIA | CELL LYMPHOPROLIFERATIVE DISORDERS | B-CELL | ONCOLOGY | FRACTIONATED CYCLOPHOSPHAMIDE | GM-CSF | HODGKIN LYMPHOMA | LIPOSOMAL DAUNORUBICIN | FLUDARABINE | EPSTEIN-BARR-VIRUS | MUTATIONAL STATUS | Predictive Value of Tests | Genetic Predisposition to Disease | Lymphoma, Large B-Cell, Diffuse - pathology | Humans | Risk Factors | Treatment Outcome | Gene Expression Regulation, Leukemic | Leukemia, Lymphocytic, Chronic, B-Cell - genetics | Disease Progression | Leukemia, Lymphocytic, Chronic, B-Cell - pathology | Lymphoma, Large B-Cell, Diffuse - mortality | Stem Cell Transplantation | Diagnostic Imaging | Leukemia, Lymphocytic, Chronic, B-Cell - therapy | Lymphoma, Large B-Cell, Diffuse - therapy | Phenotype | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Biopsy | Immunotherapy | Lymphoma, Large B-Cell, Diffuse - immunology | Leukemia, Lymphocytic, Chronic, B-Cell - mortality | Leukemia, Lymphocytic, Chronic, B-Cell - immunology | Lymphoma, Large B-Cell, Diffuse - genetics
Journal Article
Details down arrow
7. Full Text Long-term follow-up of treatment with ibrutinib and rituximab in patients with high-risk chronic lymphocytic leukemia
by Jain, Preetesh and Keating, Michael J and Wierda, William G and Sivina, Mariela and Thompson, Philip A and Ferrajoli, Alessandra and Estrov, Zeev and Kantarjian, Hagop and O'Brien, Susan and Burger, Jan A
Clinical Cancer Research, ISSN 1078-0432, 05/2017, Volume 23, Issue 9, pp. 2154 - 2158
Background: Ibrutinib is an active therapy with an acceptable safety profile for patients with chronic lymphocytic leukemia (CLL), including high-risk patients... 
TRIAL | CLL | ONCOLOGY | INITIAL THERAPY | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Follow-Up Studies | Pyrimidines - administration & dosage | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Remission Induction | Leukemia, Lymphocytic, Chronic, B-Cell - pathology | Rituximab - administration & dosage | Disease-Free Survival | Pyrazoles - administration & dosage | Pyrimidines - adverse effects | Adult | Female | Aged | Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy | Pyrazoles - adverse effects | Rituximab - adverse effects | Therapy | Chronic lymphatic leukemia | Cell survival | Risk groups | Leukemia | p53 Protein | Medical treatment | Stem cell transplantation | Rituximab | Risk | Transplantation | Lymphatic leukemia | Survival | Patients | Clonal deletion | Experimental design | Safety engineering | Deletion | Remission | Fatalities | Mutation | Cancer | deletion 17p | chronic lymphocytic leukemia | Ibrutinib | rituximab
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Richter's transformation in CLL—a distinct lymphoma
by Jain, Preetesh and Young, Ken H
Nature Reviews Clinical Oncology, ISSN 1759-4774, 01/2014, Volume 11, Issue 1, pp. 6 - 8
A landmark study has delineated and identified the genetic pathways that drive the natural course of chronic lymphocytic leukaemia (CLL) B cells into Richter's... 
Genetic aspects | Diagnosis | Gene mutations | Identification and classification | Richter's syndrome
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Anti-CD20 monoclonal antibodies in chronic lymphocytic leukemia
by Jain, Preetesh and O'Brien, Susan
Expert Opinion in Biological Therapy, ISSN 1471-2598, 02/2013, Volume 13, Issue 2, pp. 169 - 182
Introduction: The last decade has witnesd immense progress in the treatment of chronic lymphocytic leukemia (CLL). Chemoimmunotherapy (CIT) combining rituximab... 
Fc receptors | Chronic lymphatic leukemia | Cyclophosphamide | Conferences | Clinical trials | Monoclonal antibodies | fludarabine | Oncology | rituximab
Journal Article
Details down arrow
10. Full Text CLL progression after one cycle of FCR: Richter's transformation versus EBV-associated lympho-proliferation
by Jain, Preetesh and Burger, Jan A and Khoury, Joseph D
American Journal of Hematology, ISSN 0361-8609, 10/2017, Volume 92, Issue 10, pp. 1113 - 1114
HEMATOLOGY | PATIENT | LEUKEMIA | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Middle Aged | Male | Epstein-Barr Virus Infections - drug therapy | Herpesvirus 4, Human | Leukemia, Lymphocytic, Chronic, B-Cell - pathology | Epstein-Barr Virus Infections - pathology | Leukemia, Lymphocytic, Chronic, B-Cell - diagnostic imaging | Epstein-Barr Virus Infections - diagnostic imaging | Leukemia, Lymphocytic, Chronic, B-Cell - metabolism | Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy | Epstein-Barr Virus Infections - metabolism
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Flower cells of leukemia
by Jain, Preetesh and Prabhash, Kumar
Blood, ISSN 0006-4971, 03/2010, Volume 115, Issue 9, pp. 1668 - 1668
HEMATOLOGY
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text "cup-like" blasts and NPM1 and FLT3 (ITD) mutations in acute myeloid leukemia (AML)
by Jain, Preetesh and Vega-Vazquez, Francisco and Faderl, Stefan
International Journal of Hematology, ISSN 0925-5710, 07/2013, Volume 98, Issue 1, pp. 3 - 3
Byline: Preetesh Jain (1), Francisco Vega-Vazquez (1), Stefan Faderl (1) Author Affiliation: (1) MD Anderson Cancer Center, University of Texas, Houston, TX,... 
HEMATOLOGY | Leukemia, Myeloid, Acute - pathology | Humans | Leukemia, Myeloid, Acute - metabolism | Bone Marrow Cells - pathology | Male | Nuclear Proteins - metabolism | Leukemia, Myeloid, Acute - blood | Tandem Repeat Sequences | fms-Like Tyrosine Kinase 3 - metabolism | fms-Like Tyrosine Kinase 3 - genetics | Cell Nucleus Shape | Cell Shape | Aged | Mutation | Nuclear Proteins - genetics | Leukemia, Myeloid, Acute - genetics
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib
by Jain, Preetesh and Keating, Michael and Wierda, William and Estrov, Zeev and Ferrajoli, Alessandra and Jain, Nitin and George, Binsah and James, Danelle and Kantarjian, Hagop and Burger, Jan and O'Brien, Susan
Blood, ISSN 0006-4971, 03/2015, Volume 125, Issue 13, pp. 2062 - 2067
Ibrutinib is a Bruton tyrosine kinase inhibitor approved for the treatment of patients with relapsed refractory chronic lymphocytic leukemia (RR-CLL). We... 
HEMATOLOGY | LYMPHOMA | BRUTONS TYROSINE KINASE | Clinical Trials as Topic - mortality | Pyrazoles - therapeutic use | Prognosis | Humans | Middle Aged | Antineoplastic Agents - therapeutic use | Cell Transformation, Neoplastic - chemically induced | Withholding Treatment - statistics & numerical data | Disease Progression | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Survival Analysis | Aged, 80 and over | Adult | Aged | Leukemia, Lymphocytic, Chronic, B-Cell - mortality | Retrospective Studies | Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy | Leukemia, Lymphocytic, Chronic, B-Cell - diagnosis | Clinical Trials and Observations
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
14. Full Text Recent advances in de novo CD5+ diffuse large B cell lymphoma
by Jain, Preetesh and Fayad, Luis E and Rosenwald, Andreas and Young, Ken H and O'Brien, Susan
American Journal of Hematology, ISSN 0361-8609, 09/2013, Volume 88, Issue 9, pp. 798 - 802
Various subsets of DLBCL are distinguished based on molecular and immunohistochemical features. CD5 expressing DLBCL (CD5+ DLBCL) is increasingly recognized as... 
SURVIVAL | BIOMARKERS | TRANSFORMATION | MICROARRAY | RITUXIMAB | GENE-EXPRESSION | DISTINCT SUBGROUPS | COMPARATIVE GENOMIC HYBRIDIZATION | IDENTIFICATION | HEMATOLOGY | CHEMOTHERAPY | L-Lactate Dehydrogenase - metabolism | CD5 Antigens - genetics | Gene Expression | Lymphoma, Large B-Cell, Diffuse - drug therapy | Age Factors | Lymphoma, Large B-Cell, Diffuse - pathology | Humans | Rituximab | Treatment Outcome | Antineoplastic Agents - therapeutic use | CD5 Antigens - metabolism | Lymphoma, Large B-Cell, Diffuse - mortality | B-Lymphocytes - drug effects | L-Lactate Dehydrogenase - genetics | Sex Factors | Survival Analysis | Aged | B-Lymphocytes - pathology | Neoplasm Staging | Lymphoma, Large B-Cell, Diffuse - genetics | B-Lymphocytes - metabolism | Antibodies, Monoclonal, Murine-Derived - therapeutic use | Chemotherapy | Lymphomas | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
15. Full Text Biclonal IGHV‐4‐34 hairy cell leukemia variant and CLL ‐ successful treatment with ibrutinib and venetoclax
by Jain, Preetesh and Kanagal‐Shamanna, Rashmi and Konoplev, Sergej and Zuo, Zhuang and Estrov, Zeev
American Journal of Hematology, ISSN 0361-8609, 12/2018, Volume 93, Issue 12, pp. 1568 - 1569
HEMATOLOGY | Leukemia, Lymphocytic, Chronic, B-Cell - therapy | Pyrazoles - therapeutic use | Sulfonamides - therapeutic use | Bridged Bicyclo Compounds, Heterocyclic - therapeutic use | Pyrimidines - therapeutic use | Humans | Leukemia, Hairy Cell - genetics
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
16. Full Text Chronic Myeloid Leukemia: Overview of New Agents and Comparative Analysis
by Jain, Preetesh and Kantarjian, Hagop and Cortes, Jorge
Current Treatment Options in Oncology, ISSN 1527-2729, 6/2013, Volume 14, Issue 2, pp. 127 - 143
Discovery of targeted BCR-ABL protein tyrosine kinase inhibitors (TKI) in the therapy of patients with chronic myeloid leukemia (CML) is perhaps the most... 
Nilotinib | Dasatinib | Imatinib | Medicine & Public Health | BCR-ABL tyrosine kinase | Oncology | Chronic myeloid leukemia | Omacetaxine | Ponatinib | Bosutinib | Tyrosine kinase inhibitors | CHRONIC MYELOGENOUS LEUKEMIA | BCR-ABL MUTATIONS | 2-YEAR FOLLOW-UP | HIGH-DOSE IMATINIB | SMALL-MOLECULE INHIBITOR | CANCER STEM-CELLS | 400 MG | FRONT-LINE TREATMENT | ONCOLOGY | DIAGNOSED CHRONIC-PHASE | Protein Kinase Inhibitors - therapeutic use | Protein-Tyrosine Kinases - metabolism | Humans | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - metabolism | Drug Resistance, Neoplasm | Clinical Trials as Topic | Protein-Tyrosine Kinases - antagonists & inhibitors | Randomized Controlled Trials as Topic | Comparative analysis | Drug resistance | Patient compliance | Stem cells
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
17. Full Text Haematological cancer: Richter's transformation in CLL - A distinct lymphoma
by Jain, Preetesh and Young, Ken H
Nature Reviews Clinical Oncology, ISSN 1759-4774, 01/2014, Volume 11, Issue 1, pp. 6 - 8
A landmark study has delineated and identified the genetic pathways that drive the natural course of chronic lymphocytic leukaemia (CLL) B cells into Richter's... 
CHRONIC LYMPHOCYTIC-LEUKEMIA | RISK | IMPACT | MUTATIONS | ONCOLOGY | Lymphoma, Large B-Cell, Diffuse - drug therapy | Lymphoma, Large B-Cell, Diffuse - pathology | Humans | Antineoplastic Agents - therapeutic use | Receptors, Antigen, B-Cell - antagonists & inhibitors | Leukemia, Lymphocytic, Chronic, B-Cell - genetics | Leukemia, Lymphocytic, Chronic, B-Cell - pathology | Signal Transduction - drug effects | Cell Transformation, Neoplastic - genetics | Pre-B Cell Receptors - antagonists & inhibitors | Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy | Cell Transformation, Neoplastic - pathology | Lymphoma, Large B-Cell, Diffuse - genetics
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights